The Discounted Cash Flow (DCF) valuation of Boston Therapeutics Inc (BTHE) is (0.04) USD. With the latest stock price at 0.03 USD, the upside of Boston Therapeutics Inc based on DCF is -212.7%.
Based on the latest price of 0.03 USD and our DCF valuation, Boston Therapeutics Inc (BTHE) is a sell. selling BTHE stocks now will result in a potential gain of 212.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.4% - 6.6% | 5.5% |
| Long-term Growth Rate | 3.0% - 4.2% | 3.6% |
| Fair Price | (0.31) - (0.02) | (0.04) |
| Upside | -1021.6% - -156.8% | -212.7% |